keyword
MENU ▼
Read by QxMD icon Read
search

Scaffold stent

keyword
https://www.readbyqxmd.com/read/29147473/bioresorbable-vascular-scaffold-versus-metallic-stent-in-percutaneous-coronary-intervention-results-of-the-aida-trial
#1
Syed Raza Shah, Mazia Fatima, Amin Muhammad Dharani, Waqas Shahnawaz, Syed Arbab Shah
Drug-eluting stents have significantly improved the long-term outcomes of percutaneous coronary intervention (PCI) by decreasing the excessive growth of neointima. However, conventional stents have some limitations. PCI with a bioresorbable vascular scaffold (BVS) has emerged as an alternative since the presence of the prosthesis in the coronary artery is transient. A US Food and Drug Administration advisory panel of experts recommended approval of BVS based on the analysis of its risks and rewards in July 2016...
2017: Journal of Community Hospital Internal Medicine Perspectives
https://www.readbyqxmd.com/read/29131802/acute-and-one-year-clinical-outcomes-following-implantation-of-bioresorbable-vascular-scaffolds-the-absorb-uk-registry
#2
Andreas Baumbach, Azfar Zaman, Nick Ej West, Peter O'Kane, Mohaned Egred, Thomas Johnson, Stephen Wheatcroft, Bowles Ruth, Adam de Belder, Georgious Bouras, Alexandra Lansky, Jonathan Hill, Anthony Mathur, Mark A de Belder, Adrian Banning
AIMS: The aim was to monitor practice patterns and outcomes in patients treated with Absorb bioresorbable vascular scaffolds (BVS) during the early phase of usage in the UK. METHODS AND RESULTS: A total of 1005 patients with de-novo coronary lesions were treated using careful implantation techniques at 24 centers. Follow-up at one year was obtained in 99%. An independent clinical event committee and angiographic corelab adjudicated all events. Patient age was 52 years and 46% presented with acute coronary syndromes...
November 14, 2017: EuroIntervention
https://www.readbyqxmd.com/read/29131799/multi-slice-computed-tomography-assessment-of-everolimus-eluting-absorb-bioresorbable-scaffold-in-comparison-with-metallic-drug-eluting-stents-from-the-absorb-japan-randomized-trial
#3
Kengo Tanabe, Jeffrey J Popma, Ken Kozuma, Shigeru Saito, Toshiya Muramatsu, Sunao Nakamura, Atsuo Namiki, Yoshihiro Morino, Nobuhisa Hagiwara, Masaaki Uematsu, Tomohiro Kawasaki, Kenshi Fujii, Patrick W Serruys, Yoshinobu Onuma, Shihwa Ying, Hajime Kusano, Gregg W Stone, Takeshi Kimura
AIMS: Blooming artifacts limit accurate coronary assessment by multi-slice computed tomography (MSCT) in metallic stents. We sought to investigate whether bioresorbable vascular scaffold (BVS) could be better assessed by MSCT. Methods and Results: Among 400 patients in the randomized ABSORB Japan trial, a pre-specified MSCT sub-study was performed in 98 patients (103 lesions) in the BVS arm and 49 patients (49 lesions) in the cobalt chromium everolimus-eluting stent (CoCr-EES) arm at 13-month prior to follow-up angiography...
November 14, 2017: EuroIntervention
https://www.readbyqxmd.com/read/29122816/local-hemodynamic-forces-after-stenting-implications-on-restenosis-and-thrombosis
#4
REVIEW
Jaryl Ng, Christos V Bourantas, Ryo Torii, Hui Ying Ang, Erhan Tenekecioglu, Patrick W Serruys, Nicolas Foin
Local hemodynamic forces are well-known to modulate atherosclerotic evolution, which remains one of the largest cause of death worldwide. Percutaneous coronary interventions with stent implantation restores blood flow to the downstream myocardium and is only limited by stent failure caused by restenosis, stent thrombosis, or neoatherosclerosis. Cumulative evidence has shown that local hemodynamic forces affect restenosis and the platelet activation process, modulating the pathophysiological mechanisms that lead to stent failure...
November 9, 2017: Arteriosclerosis, Thrombosis, and Vascular Biology
https://www.readbyqxmd.com/read/29118997/long-and-short-of-optimal-stent-design
#5
REVIEW
Timothy Watson, Mark W I Webster, John A Ormiston, Peter N Ruygrok, James T Stewart
The ideal stent must fulfil a broad range of technical requirements. Stents must be securely crimped onto the delivery balloon and, in this form, must have a low profile and be sufficiently flexible to facilitate deliverability to the lesion site without distortion or displacement. Following expansion, stents must exert sufficient radial force on the vessel wall to overcome lesion resistance and elastic recoil. To achieve an optimal lumen diameter, the lesion must be uniformly and adequately scaffolded, with minimal tissue prolapse between struts but without compromising side-branch access...
2017: Open Heart
https://www.readbyqxmd.com/read/29118792/anchoring-pipeline-flow-diverter-construct-in-the-treatment-of-traumatic-distal-cervical-carotid-artery-injury
#6
Krishna Amuluru, Fawaz Al-Mufti, William Roth, Charles J Prestigiacomo, Chirag D Gandhi
Background: Traumatic extracranial internal carotid artery (ICA) dissections are uncommon and can be difficult to treat. Thinning of adventitia and dilatation may occur following arterial dissection, thus resulting in a fusiform pseudoaneurysm, which can subsequently cause bleeding, expanding, or pulsatile hematoma. Currently, medical management with anticoagulation remains the first line of treatment and yields good outcomes in 75% of cases with a mortality rate of 3-4%. Endovascular intervention is indicated with failure of medical therapy, progressive enlargement of a traumatic pseudoaneurysm, acute flow-related infarcts due to vessel occlusion, or when anticoagulation is contraindicated due to risk of pseudoaneurysm rupture and hemorrhage...
October 2017: Interventional Neurology
https://www.readbyqxmd.com/read/29113720/spanish-cardiac-catheterization-and-coronary-intervention-registry-26th-official-report-of-the-spanish-society-of-cardiology-working-group-on-cardiac-catheterization-and-interventional-cardiology-1990-2016
#7
Ana María Serrador Frutos, Pilar Jiménez-Quevedo, Armando Pérez de Prado, Manuel Pan Álvarez-Ossorio
INTRODUCTION AND OBJECTIVES: The Working Group on Cardiac Catheterization and Interventional Cardiology presents its annual report on the activity data for 2016. METHODS: All Spanish hospitals with catheterization laboratories were invited to voluntarily contribute their activity data. The information was collected online and was analyzed mainly by an independent company. RESULTS: In 2016, 106 centers participated in the national registry; 80 of these centers are public...
November 4, 2017: Revista Española de Cardiología
https://www.readbyqxmd.com/read/29108400/early-experience-and-favorable-clinical-outcomes-of-everolimus-eluting-bioresorbable-scaffolds-for-coronary-artery-disease-in-korea
#8
Osung Kwon, Jung-Min Ahn, Do-Yoon Kang, Se Hun Kang, Pil Hyung Lee, Soo-Jin Kang, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Duk-Woo Park, Seung-Jung Park
Background/Aims: Compared with metallic drug-eluting stents (DES), bioresorbable vascular scaffolds (BVS) may further improve long-term outcomes of percutaneous coronary intervention (PCI) in patients with coronary artery disease. We report our early experience with BVS in Korea. Methods: We evaluated 105 consecutive patients with BVS implanted at Asan Medical Center, Korea between October 21, 2015 and June 3, 2016. Angiographic results, and in-hospital and 6-month clinical outcomes were assessed...
November 7, 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29106056/microenvironmental-stiffness-of-3d-polymeric-structures-to-study-invasive-rates-of-cancer-cells
#9
Enrico Domenico Lemma, Barbara Spagnolo, Francesco Rizzi, Stefania Corvaglia, Marco Pisanello, Massimo De Vittorio, Ferruccio Pisanello
Cells are highly dynamic elements, continuously interacting with the extracellular environment. Mechanical forces sensed and applied by cells are responsible for cellular adhesion, motility, and deformation, and are heavily involved in determining cancer spreading and metastasis formation. Cell/extracellular matrix interactions are commonly analyzed with the use of hydrogels and 3D microfabricated scaffolds. However, currently available techniques have a limited control over the stiffness of microscaffolds and do not allow for separating environmental properties from biological processes in driving cell mechanical behavior, including nuclear deformability and cell invasiveness...
November 6, 2017: Advanced Healthcare Materials
https://www.readbyqxmd.com/read/29100702/3-year-clinical-outcomes-with-everolimus-eluting-bioresorbable-coronary-scaffolds-the%C3%A2-absorb-iii-trial
#10
Dean J Kereiakes, Stephen G Ellis, Christopher Metzger, Ronald P Caputo, David G Rizik, Paul S Teirstein, Marc R Litt, Annapoorna Kini, Ameer Kabour, Steven O Marx, Jeffrey J Popma, Robert McGreevy, Zhen Zhang, Charles Simonton, Gregg W Stone
BACKGROUND: The Absorb everolimus-eluting poly-L-lactic acid-based bioresorbable vascular scaffold (BVS) provides early drug delivery and mechanical support functions similar to metallic drug-eluting stents (DES), followed by complete bioresorption in approximately 3 years with recovery of vascular structure and function. The ABSORB III trial demonstrated noninferior rates of target lesion failure (cardiac death, target vessel myocardial infarction [TVMI], or ischemia-driven target lesion revascularization) at 1 year in 2,008 patients with coronary artery disease randomized to BVS versus cobalt-chromium everolimus-eluting stents (EES)...
October 20, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29096803/mechanisms-of-very-late-bioresorbable%C3%A2-scaffold-thrombosis-the-invest-registry
#11
Kyohei Yamaji, Yasushi Ueki, Geraud Souteyrand, Joost Daemen, Jens Wiebe, Holger Nef, Tom Adriaenssens, Joshua P Loh, Benoit Lattuca, Joanna J Wykrzykowska, Josep Gomez-Lara, Leo Timmers, Pascal Motreff, Petra Hoppmann, Mohamed Abdel-Wahab, Robert A Byrne, Felix Meincke, Niklas Boeder, Benjamin Honton, Crochan J O'Sullivan, Alfonso Ielasi, Nicolas Delarche, Günter Christ, Joe K T Lee, Michael Lee, Nicolas Amabile, Alexios Karagiannis, Stephan Windecker, Lorenz Räber
BACKGROUND: Very late scaffold thrombosis (VLScT) occurs more frequently after bioresorbable scaffold (Absorb BVS 1.1, Abbott Vascular, Santa Clara, California) implantation than with metallic everolimus-eluting stents. OBJECTIVES: The purpose of this study was to elucidate mechanisms underlying VLScT as assessed by optical coherence tomography (OCT). METHODS: The INVEST (Independent OCT Registry on Very Late Bioresorbable Scaffold Thrombosis) registry is an international consortium of investigators who used OCT to examine patients with VLScT...
November 7, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29094677/four-year-follow-up-of-the-randomised-comparison-between-an-everolimus-eluting-bioresorbable-scaffold-and-an-everolimus-eluting-metallic-stent-for-the-treatment-of-coronary-artery-stenosis-absorb-ii-trial
#12
Bernard Chevalier, Angel Cequier, Dariusz Dudek, Michael Haude, Didier Carrie, Manel Sabaté, Stephan Windecker, Sebastian Reith, Manuel de Sousa Almeida, Gianluca Campo, Andres Iñiguez, Yoshi Onuma, Patrick W Serruys
AIMS: No randomised comparison data are available beyond the resorption of the everolimus-eluting bioresorbable scaffold. Absorb is expected to be completely resorbed by 3 years. The purpose of this report is to provide the 4 year results of a randomised, single blind, multicentre evaluation of Absorb versus the metallic stent Xience (Abbott Vascular, Santa Clara, CA, USA). METHODS AND RESULTS: Three-year follow-up has been previously published. Patients re-consented for additional follow-up up through to 5 years; 86% (N=289) and 84% (N=139) of whom underwent a 4 year follow-up visit...
October 31, 2017: EuroIntervention
https://www.readbyqxmd.com/read/29091563/bioresorbable-scaffolds-versus-metallic-stents-in-routine-pci
#13
LETTER
Robin P Kraak, Joanna J Wykrzykowska
New England Journal of Medicine, Volume 377, Issue 18, Page 1790-1792, November 2017.
November 2, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29089314/three-year-outcomes-with-the-absorb-bioresorbable-scaffold-individual-patient-data-meta-analysis-from-the-absorb-randomized-trials
#14
Ziad A Ali, Runlin F Gao, Takeshi Kimura, Yoshinobu Onuma, Dean J Kereiakes, Stephen G Ellis, Bernard Chevalier, Minh-Thien Vu, Zhen Zhang, Charles A Simonton, Patrick W Serruys, Gregg W Stone
BACKGROUND : The Absorb bioresorbable vascular scaffold (BVS) completely resorbs within 3 years after coronary artery implantation. The safety and effectiveness of BVS through this critical 3-year period have not been characterized. METHODS : We performed an individual-patient-data pooled meta-analysis of the 4 randomized ABSORB trials in which 3389 patients with coronary artery disease were randomly assigned to everolimus-eluting Absorb BVS (n=2164) or cobalt-chromium everolimus-eluting stents (n=1225). The primary efficacy outcome measure was target lesion failure (cardiac mortality, target vessel myocardial infarction, or ischemia-driven target lesion revascularization), and the primary safety outcome measure was device thrombosis...
October 31, 2017: Circulation
https://www.readbyqxmd.com/read/29081013/emerging-technologies-in-flow-diverters-and-stents-for-cerebrovascular-diseases
#15
REVIEW
Michael Karsy, Jian Guan, Andrea A Brock, Anubhav Amin, Min S Park
PURPOSE OF REVIEW: Stents and flow diverters have revolutionized the treatment of cerebrovascular disease. Guglielmi coils, flexible microcatheters, and first-generation intracranial stents, such as Neuroform (Stryker Neurovascular) and Enterprise stents (Codman/DePuy-Synthes), have paved the way for the development of the Pipeline Embolization Device (PED) (ev3/Covidien/Medtronic) and other endovascular approaches. RECENT FINDINGS: This review discusses the historical development of flow diverter technologies from the PED to similar devices, such as the Surpass stent (Stryker Neurovascular), the Flow-Redirection Endoluminal Device (FRED; MicroVention, Inc...
October 28, 2017: Current Neurology and Neuroscience Reports
https://www.readbyqxmd.com/read/29080150/in-stent-fractional-flow-reserve-variations-and-related-optical-coherence-tomography-findings-the-ffr-oct-co-registration-study
#16
Stylianos A Pyxaras, Tom Adriaenssens, Emanuele Barbato, Giovanni Jacopo Ughi, Luigi Di Serafino, Frederic De Vroey, Gabor Toth, Shengxian Tu, Johan H C Reiber, Jeroen J Bax, William Wijns
We sought to assess in-stent variations in fractional flow reserve (FFR) in patients with previous percutaneous coronary intervention (PCI) and to associate any drop in FFR with findings by optical coherence tomography (OCT) imaging. Suboptimal post-PCI FFR values were previously associated with poor outcomes. It is not known to which extent in-stent pressure loss contributes to reduced FFR. In this single-arm observational study, 26 patients who previously underwent PCI with drug-eluting stent or scaffold implantation were enrolled...
October 27, 2017: International Journal of Cardiovascular Imaging
https://www.readbyqxmd.com/read/29076827/one-year-imaging-follow-up-of-a-self-expanding-bifurcation-drug-eluting-stent-and-bioresorbable-scaffold-for-a-complex-bifurcation-lesion
#17
Akihiro Nakajima, Hiroyoshi Kawamoto, Sunao Nakamura, Damras Tresukosol
No abstract text is available yet for this article.
October 25, 2017: Coronary Artery Disease
https://www.readbyqxmd.com/read/29049539/mid-and-long-term-outcome-comparisons-of-everolimus-eluting-bioresorbable-scaffolds-versus-everolimus-eluting-metallic-stents-a-systematic-review-and-meta-analysis
#18
REVIEW
Xin-Lin Zhang, Qing-Qing Zhu, Li-Na Kang, Xue-Ling Li, Biao Xu
Background: Percutaneous coronary interventions to implant bioresorbable vascular scaffolds (BVSs) were designed to reduce the late thrombotic events that occur with metallic stents. Purpose: To estimate the incidence of scaffold thrombosis after BVS implantation and compare everolimus-eluting BVSs with everolimus-eluting metallic stents (EESs) in terms of safety and efficacy at mid- and long-term follow-up in adults who had a percutaneous coronary intervention...
November 7, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/29043405/-focused-update-on-dual-antiplatelet-treatment-esc-guidelines-2017
#19
A Schäfer, J Bauersachs
Dual antiplatelet treatment (DAPT) is a cornerstone of maintenance medication of patients following elective percutaneous coronary interventions or an acute coronary syndrome (ACS), e. g. ST elevation myocardial infarction, non-ST elevation myocardial infarction and unstable angina. In recent years the inclusion of P2Y12 inhibition in addition to low-dose acetylsalicylic acid has been intensively debated. Following the introduction of the modern generation of drug-eluting stents for elective coronary interventions, the duration of the necessary DAPT has been clearly reduced...
October 17, 2017: Herz
https://www.readbyqxmd.com/read/29033836/delivery-of-antioxidant-and-anti-inflammatory-agents-for-tissue-engineered-vascular-grafts
#20
REVIEW
Kenyatta S Washington, Chris A Bashur
The treatment of patients with severe coronary and peripheral artery disease represents a significant clinical need, especially for those patients that require a bypass graft and do not have viable veins for autologous grafting. Tissue engineering is being investigated to generate an alternative graft. While tissue engineering requires surgical intervention, the release of pharmacological agents is also an important part of many tissue engineering strategies. Delivery of these agents offers the potential to overcome the major concerns for graft patency and viability...
2017: Frontiers in Pharmacology
keyword
keyword
117505
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"